Italia markets close in 3 hours
FTSE MIB
34.762,50 +270,09 (+0,78%) Dow Jones
38.686,32 +574,82 (+1,51%) Nasdaq
16.735,02 -2,08 (-0,01%) Nikkei 225
38.923,03 +435,13 (+1,13%) Petrolio
77,10 +0,11 (+0,14%) Bitcoin EUR
63.964,09 +1.302,32 (+2,08%)
Scorpius Holdings, Inc. (1HB.F)
Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
In data: 08:16AM CEST. Mercato aperto.
| Chiusura precedente | 0,1280 |
| Aperto | 0,1280 |
| Denaro | 0,0000 x N/D |
| Domanda | 0,0000 x N/D |
| Min-Max giorno | 0,1280 - 0,1280 |
| Intervallo di 52 settimane | 0,0975 - 0,7600 |
| Volume | |
| Media Volume | 319 |
| Capitalizzazione | 12,373M |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,1400 |
| Prossima data utili | 12 ago 2024 - 16 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 20,67 |
GlobeNewswireNightHawk Biosciences Provides Q2 2023 Business Update
DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative medical countermeasures that combat unmet and emerging biothreats, today provided strategic, financial, and operational updates for the quarter ended June 30, 2023. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “Development of our biomanufacturing opera
© 2024 Yahoo. Tutti i diritti riservati.